13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

45 trials found

diseases per page:

Showing 1 to 10 of 45 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05758831 (ClinicalTrials.gov)	February 28, 2023	17/2/2023	RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.	A Prospective Randomized Trial of Non-inferiority Comparing RItuximabVersus Ocrelizumab in Relapsing ...	Multiple Sclerosis;Relapsing-remitting Multiple Sclerosis	Drug: Perfusion of treatment Rituximab;Drug: Perfusion of treatment Ocrelizumab	Rennes University Hospital	NULL	Not yet recruiting	18 Years	55 Years	All	386	Phase 3	France
2	EUCTR2020-001205-23-SE (EUCTR)	08/02/2022	06/12/2021	Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease	Ocrelizumab VErsus Rituximaboff-Label at the Onset of RelapsingMS Disease (OVERLORD-MS) - OVERLORD-M ...	Remitting Relapsing Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus Product Name: Ocrelizumab Trade Name: Rituximab Product Name: Rituximab	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	211	Phase 3	Sweden
3	EUCTR2021-001973-21-SE (EUCTR)	09/07/2021	04/06/2021	Extension of Study GNC-401 with temelimab in patients with Multiple Sclerosis under treatment with r ...	A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple S ...	Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multi ...	Product Name: Temelimab Product Code: GNbAC1 INN or Proposed INN: TEMELIMAB Product Name: Temelimab Prod ...	GeNeuro Innovation SAS	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2	Sweden
4	NCT04688788 (ClinicalTrials.gov)	April 28, 2021	22/12/2020	Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Danish Non-inferiority Study of Ocrelizumab and Rituximabin MS (DanNORMS): A Randomized Study Compar ...	Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive ...	Drug: Rituximab;Drug: Ocrelizumab;Drug: Fexofenadine;Drug: Paracetamol;Drug: Methylprednisolone	Rigshospitalet, Denmark	Odense University Hospital;Aarhus University Hospital;Aalborg University Hospital;Herlev Hospital;Hi ...	Recruiting	18 Years	65 Years	All	594	Phase 3	Denmark
5	ChiCTR2100043013	2021-01-31	2021-02-04	Efficacy difference between low dose rituximaband mycophenolate mofetil in preventing recurrence of ...	Efficacy difference between low dose rituximaband mycophenolate mofetil in preventing recurrence of ...	Neuromyelitis optica spectrum diseases	low dose rituximab group: low dose rituximab ;mycophenolate mofetil group:mycophenolate mofetil ;	Shandong University Qilu Hospital	NULL	Pending			Both	low dose rituximab group:30;mycophenolate mofetil group:30;	Phase 4	China
6	NCT04640818 (ClinicalTrials.gov)	December 17, 2020	18/11/2020	Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy	Safety and Efficacy of a Therapy With Cladribine Following a Treatment With Anti CD20 Compounds in R ...	Multiple Sclerosis	Drug: Cladribine Oral Tablet;Drug: Rituximab;Drug: Ocrelizumab	Claudio Gobbi	Merck AG Switzerland	Active, not recruiting	18 Years	80 Years	All	45		Switzerland
7	EUCTR2020-002981-15-DK (EUCTR)	15/12/2020	13/07/2020	Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis.	Danish non-inferiority study of ocrelizumab and rituximabin MS (DanNORMS): A randomized study compar ...	Multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063400;Term: Secondary prog ...	Trade Name: Ocrevus INN or Proposed INN: ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Ru ...	Danish Multiple Sclerosis Center, Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	594	Phase 3	Denmark
8	NCT04578639 (ClinicalTrials.gov)	November 2, 2020	22/9/2020	Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease	Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing	Relapsing Remitting Multiple Sclerosis	Drug: Rituximab;Drug: Ocrelizumab	Haukeland University Hospital	University Hospital, Akershus;Oslo University Hospital;Helse Stavanger HF;St. Olavs Hospital;Univers ...	Recruiting	18 Years	60 Years	All	211	Phase 3	Norway;Sweden
9	EUCTR2019-004822-15-SE (EUCTR)	18/05/2020	17/01/2020	A Clinical Trial Examining the Effects of Temelimab Following RituximabTreatment in Patients with Mu ...	A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacody ...	Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multi ...	Product Name: Temelimab Product Code: GNbAC1 INN or Proposed INN: temelimab Product Name: Temelimab Prod ...	GeNeuro Innovation SAS	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2	Sweden
10	NCT03829566 (ClinicalTrials.gov)	November 2019	1/2/2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;B ...	Northwestern University	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 2/Phase 3	United States

First Previous1 2 3 4 5Next Last